TTPH, Tetraphase Pharmaceuticals | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
TTPH, Tetraphase Pharmaceuticals

An SI Board Since January 2016

Posts	SubjectMarks	Bans	Symbol
80	17	0	TTPH

Emcee: scaram(o)uche	Type: Moderated

Introduction Market Data Compact

Tetraphase has hit a snag, failing inferiority testing with an antibiotic at phase III. The company should be considered as having two phase I clinical trial programs, with one of those molecules having passed a single phase III trial. Current plans are to file in Europe for eravacycline, but it's back to phase I for the U.S.

Last share offering, 3/15, was at $35.

Current shares (1/28/16) are going for $5.18.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
80	U.S. FDA approves Tetraphase Pharma's antibiotic finance.yahoo.com	Julius Wong	-	8/30/2018
79	I never take my due from class action suits. Last one I participated in was Ela	scaram(o)uche	-	7/31/2018
78	Yup. I'd be more interested in this for its remaining early stage programs,	tuck	-	2/15/2018
77	When it happens twice in 18 months it's hard to make the argument that manag	HardToFind	-	2/15/2018
76	Here’s What’s Moving Tetraphase Tetraphase Pharmaceuticals, Inc. ( NASDAQ:TTPH)	HardToFind	-	2/14/2018
75	So with the Eravacycline program presumably dead, does the remaining pipe look c	tuck	-	2/13/2018
74	Sadly, every poorly managed public company will do the same. Only the well manag	HardToFind	-	1/23/2018
73	What would it take for someone on the Board to say..... "No, no, no, no....	scaram(o)uche	-	1/23/2018
72	archive.fast-edgar.com//20180123/AR2BP22CZC2RC9ZZ272R2ZXMBLSVZZ22Z2A2/ What wou	scaram(o)uche	2	1/23/2018
71	Motley Fool article that includes a favorable discussion of TTPH: finance.yahoo	HardToFind	-	1/16/2018
70	From 200 to 250. Twice a day.	gcrispin	-	12/21/2017
69	What was the dosage change? Did they say?	HardToFind	-	12/20/2017
68	Thanks. Also a higher dosage. Obviously didn’t do enough testing the first ti	gcrispin	-	12/20/2017
67	I gather from the 14 Dec 2017 BMO presentation, it seems as though the new oral	HardToFind	-	12/18/2017
66	The Latest Press Release On Oral Dosing (11/2/2017): Presented data at IDWeek 2	HardToFind	-	11/5/2017
65	Good to know the chatter, thanks.	scaram(o)uche	-	10/9/2017
64	...suggesting compliance would be difficult with TID dosing. Not sure how that w	HardToFind	-	10/5/2017
63	Saw a tweet concerned with food effect, suggesting compliance would be difficult	tuck	-	10/5/2017
62	thefly.com Show you how important the oral has always been to this stock.	gcrispin	1	10/4/2017
61	Looks like there is a route forward, with modest development time frames. 80%	scaram(o)uche	-	10/4/2017
60	Gotcha. Plazomicin is my interest here. Building a modest position in AKAO. Se	tuck	-	9/20/2017
59	Omadacycline is a tetracycline. So, yes, I watch it as a direct competitor, mar	scaram(o)uche	-	9/20/2017
58	targets the 30S subunit of the bacterial ribosome. Actually, so do the efforts f	tuck	-	9/19/2017
57	Competing program . . . It is my understanding that 271 targets the 30S	tuck	-	9/19/2017
56	TTPH started to move up after news came out that Paratek Pharma was putting the	gcrispin	-	8/27/2017

Go to reply# or date (mm/dd/yy):